It's good to see this outcome. The amount these drug companies have overcharged the NHS is nothing short of a disgrace.
Britain’s competition watchdog has “decided to make a point” by slapping two pharmaceutical companies with record fines for unfairly boosting the price of an epilepsy drug by 2,600 per cent, lawyers said yesterday. The Competition and Markets Authority hit Pfizer and Flynn Pharma for imposing price rises on the NHS that cost £90 million over two years. The authority fined the companies a record £89.4 million and both have signalled that they will appeal the ruling. "Illegal excessive pricing is usually very difficult to prove,” said Duncan Liddell, a partner at Ashurst, the City of London law firm Ashurst. “However, here the CMA has clearly decided to make a point with a record UK fine.”